

TAF MEK melanoma - Dosing and administration - HCP

[Prescribing information](#)

Image



Image



## **TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) dosing and administration**

TAFINLAR in combination with MEKINIST is indicated in adult patients with unresectable or metastatic melanoma with a *BRAF* V600 mutation.<sup>1,2</sup>

TAFINLAR in combination with MEKINIST is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a *BRAF* V600 mutation, following complete resection.<sup>1,2</sup>

**For the full safety profile, please refer to the Summary of Product Characteristics (SmPC) for [TAFINLAR](#) and [MEKINIST](#).**

**Adverse event reporting:** Details of how to report adverse events are available at the bottom of the page. Please refer to the respective SmPC for all licensed indications.

## **Helping patients on their TAFINLAR + MEKINIST treatment journey**

**The management of adverse events (AEs) may require treatment interruption, dose reduction, or treatment discontinuation. For information on AE management with dose modification, and dosing in special populations, please click [here](#) and refer to the SmPC.**

**TAFINLAR + MEKINIST is an oral option in the adjuvant setting<sup>1,2</sup>**

**Dosing is the same for both adjuvant and metastatic patients with melanoma<sup>1,2</sup>**

**In the metastatic setting, treatment with both TAFINLAR and MEKINIST should continue until the patient no longer derives benefit or develops unacceptable toxicity<sup>1,2</sup>**

**In the adjuvant setting, patients should be treated for a period of 12 months unless there is disease recurrence or unacceptable toxicity<sup>1,2</sup>**

This key information on the dosing and administration of TAFINLAR + MEKINIST may be helpful when discussing treatment with your patients.

Please also visit the section on AE management, which includes details on how to manage dose modifications of TAFINLAR + MEKINIST should this be necessary, as well as information on dosing in special populations.

[Dose modifications](#)

**TAFINLAR + MEKINIST offers twice daily oral dosing<sup>1,2</sup>**

### **Dosing of TAFINLAR + MEKINIST**

Drug	TAFINLAR <sup>1</sup>	MEKINIST <sup>2</sup>
Usual recommended dose	Dose of TAFINLAR in combination with MEKINIST is 150 mg (two 75 mg capsules) twice daily, corresponding to a total daily dose of 300 mg	Dose of MEKINIST in combination with TAFINLAR is 2 mg (one tablet) once daily
Maximum dose	The dose should not exceed 150 mg twice daily	The dose should not exceed 2 mg once daily

#### Duration of treatment

- In the **metastatic treatment** of melanoma, patients should be treated with TAFINLAR + MEKINIST until the patient no longer derives benefit or develops

unacceptable toxicity.<sup>1,2</sup>

- In the **adjuvant treatment** of melanoma, patients should be treated for a period of 12 months unless there is disease recurrence or unacceptable toxicity.<sup>1,2</sup>

The management of AEs associated with TAFINLAR + MEKINIST treatment may require dose reduction, treatment interruption or treatment discontinuation.<sup>1,2</sup>

For more information on dose modification guidelines please refer to the TAFINLAR + MEKINIST SmPCs and visit the [dose modification](#) tab where this is described in detail.


## **Administration of TAFINLAR + MEKINIST**

## How to take TAFINLAR + MEKINIST<sup>1,2</sup>

	<b>TAFINLAR<sup>1</sup></b>	<b>MEKINIST<sup>2</sup></b>
<b>How much to take</b>	The usual dose is 150 mg (two 75 mg capsules) twice daily.	The usual dose is 2 mg (one tablet) once a day.
<b>When to take</b>	TAFINLAR should be taken twice a day, in the morning and in the evening, about 12 hours apart. The morning and evening doses of TAFINLAR should be taken at similar times every day.	MEKINIST should be taken once a day, at about the same time each day, either with the morning or with the evening dose of TAFINLAR.
<b>How to take</b>	TAFINLAR capsules should be swallowed whole with water. They should not be chewed or opened and should not be mixed with food or liquids, due to chemical instability of TAFINLAR. TAFINLAR should be taken on an empty stomach, either 1 hour before, or 2 hours after a meal.	MEKINIST should be taken orally with a full glass of water. The tablets should not be chewed or crushed and they should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal.

### Figures for illustrative purposes only

Image



Practical advice for patients on how to take their treatment and how to incorporate it into their daily lives can be found [here](#). **Please do not share this page directly with patients.**

Always encourage your patients to carefully read the [TAFINLAR](#) and [MEKINIST](#) Patient Information Leaflets (PILs) in their TAFINLAR and MEKINIST packs before starting treatment, as they contain important information.

## What to do in certain situations when taking TAFINLAR and MEKINIST<sup>1,2</sup>

**TAFINLAR**

**MEKINIST**



**If a patient forgets to take TAFINLAR or MEKINIST**

If the missed dose is less than 6 hours late, the patient must take it as soon as they remember.

If the missed dose is more than 6 hours late, the patient should skip that dose and take the next dose at the usual time. Then carry on taking the capsules at regular times as usual.

The patient must not take a double dose to make up for a missed dose.

If the missed dose is less than 12 hours late, the patient must take it as soon as they remember.

If the missed dose is more than 12 hours late, the patient should skip that dose and take the next dose at the usual time. Then carry on taking the capsules at regular times as usual.

The patient must not take a double dose to make up for a missed dose.

**If a patient vomits after taking TAFINLAR or MEKINIST**

The patient must not take the capsules or tablet again but wait until next dose is due and take it at the normal time.

**If a patient has taken more than the prescribed number of TAFINLAR capsules, MEKINIST tablets, or other medicines**

The patient must consult a doctor, pharmacist or nurse immediately, and take the medicine(s) and its packaging with them if seeing them face to face.

**Handling and storage of TAFINLAR and MEKINIST**



## **Handling of TAFINLAR and MEKINIST**

- Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<sup>1,2</sup>

## **Storage of TAFINLAR and MEKINIST**

- For storage of TAFINLAR and MEKINIST, please refer to SmPC.

Additional information is also available from your Novartis representative, who can provide you with a comprehensive healthcare professional (HCP) brochure about TAFINLAR + MEKINIST.

*BRAF* V600, mutation of the *BRAF* gene at valine (V) 600; HCP, healthcare professional; PIL, patient information leaflet; SmPC, summary of product characteristics.

## References

1. TAFINLAR (dabrafenib) Summary of Product Characteristics.
2. MEKINIST (trametinib) Summary of Product Characteristics.

UK | March 2025 | FA-11220691

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

## Source URL:

<https://www.pro.novartis.com/uk-en/medicines/oncology/tafinlar-mekinist/melanoma/management/dosing>